Kateřina Mičová

Kateřina Mičová

Auto-generated profile, based on publicly available information

Kateřina Mičová

Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2016 in Journal of Proteome Research
Verified
Journal Article
Closed access
RKRadana Karlíková
Radana Karlíková
JŠJitka Široká
Jitka Široká
DFDavid Friedecky
David Friedecky
EFEdgar Faber
Edgar Faber
MHMarcela Hrdá
Marcela Hrdá
Tomáš AdamTomáš Adam
Tomáš Adam

1 December 2010 in Clinica Chimica Acta
Verified
Journal Article
Closed access
KMKateřina Mičová
Kateřina Mičová
DFDavid Friedecky
David Friedecky
EFEdgar Faber
Edgar Faber
APAdriana Polýnková
Adriana Polýnková
Tomáš AdamTomáš Adam
Tomáš Adam

1 January 2016 in Open Biology
Verified
Journal Article
Open access
ALAnna Ligasová
Anna Ligasová
RLRadek Liboska
Radek Liboska
DFDavid Friedecky
David Friedecky
KMKateřina Mičová
Kateřina Mičová
Tomáš AdamTomáš Adam
Tomáš Adam
KKKarel Koberna
Karel Koberna
5-Ethynyl-2′-deoxyuridine (EdU) and 5-ethynyl-2′-deoxycytidine (EdC) are mainly used as markers of cellular replicational activity. Although EdU is employed as a replicational marker more frequently than EdC, its cytotoxicity is commonly much higher than the toxicity of EdC. To reveal the reason of the lower cytotoxicity of EdC, we performed a DNA analysis of five EdC-treated human cell lines. Surprisingly, not a single one of the tested cell lines contained a detectable amount of EdC in their DNA. Instead, the DNA of all the cell lines contained EdU. The content of incorporated EdU differed in particular cells and EdC-related cytotoxicity was directly proportional to the content of EdU. The results of experiments with the targeted inhibition of the cytidine deaminase (CDD) and dCMP deaminase activities indicated that the dominant role in the conversion pathway of EdC to EdUTP is played by CDD in HeLa cells. Our results also showed that the deamination itself was not able to effectively prevent the conversion of EdC to EdCTP, the conversion of EdC to EdCTP occurs with much lesser effectivity than the conversion of EdU to EdUTP and the EdCTP is not effectively recognized by the replication complex as a substrate for the synthesis of nuclear DNA.


11 January 2012 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
EFEdgar Faber
Edgar Faber
DFDavid Friedecky
David Friedecky
KMKateřina Mičová
Kateřina Mičová
ŠRŠárka Rožmanová
Šárka Rožmanová
MDMartina Divoká
Martina Divoká
Tomáš AdamTomáš Adam
Tomáš Adam

22 June 2015 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
EFEdgar Faber
Edgar Faber
MDMartina Divoká
Martina Divoká
ISIvana Skoumalová
Ivana Skoumalová
MNMartin Novák
Martin Novák
IMIvana Marešová
Ivana Marešová
KIKarel Indrák
Karel Indrák
The information about chronic myeloid leukemia (CML) patients with a deep molecular response of ≥ 4.5 log reduction (MR4.5) in whom the dose of imatinib (IM) had to be reduced to relieve toxicity is insufficient. In 205 CML patients the dose of IM was reduced in 19 (31.2%) out of 61 patients with MR4.5. The patients (12 pretreated with interferon-alpha) achieved MR4.5 after an average of 27.7 months. The duration of MR4.5 before the reduction of the dose was 16-123 (mean = 56.7) months. After the IM reduction (200 mg daily to 400 mg twice weekly for 15-90 (mean = 48) months) MR4.5 or major molecular response (MMR) was maintained in 14 (73.7%) and 2 (10.5%) patients, respectively. Three patients who lost MMR (15.8%) after the discontinuation of IM regained MR4.5 after the reintroduction of a lower dose. A lower dosage of IM should be tested for the management of side effects in patients with MR4.5 in prospective studies.